SEC FORM 4

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Maricich Yuri

(Last)

(First)

(Middle)

C/O PEAR THERAPEUTICS, INC.

200 STATE STREET, 13TH FLOOR

(Street)

BOSTON

02109

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Pear Therapeutics, Inc. [ PEAR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/03/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	12/03/2021		A		73,620	A	⁽¹⁾	73,620	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.02	12/03/2021		A		73,620		⁽²⁾	05/05/2025	Common Stock	73,620	⁽³⁾	73,620	D
Stock Option (Right to Buy)	$0.68	12/03/2021		A		44,172		⁽²⁾	12/13/2027	Common Stock	44,172	⁽⁴⁾	44,172	D
Stock Option (Right to Buy)	$0.14	12/03/2021		A		176,689		⁽²⁾	05/10/2026	Common Stock	176,689	⁽⁵⁾	176,689	D
Stock Option (Right to Buy)	$0.72	12/03/2021		A		103,068		⁽²⁾	03/21/2028	Common Stock	103,068	⁽⁶⁾	103,068	D
Stock Option (Right to Buy)	$1.08	12/03/2021		A		88,344		⁽⁷⁾	03/14/2029	Common Stock	88,344	⁽⁸⁾	88,344	D
Stock Option (Right to Buy)	$1.09	12/03/2021		A		103,068		⁽⁹⁾	03/24/2030	Common Stock	103,068	⁽¹⁰⁾	103,068	D
Stock Option (Right to Buy)	$1.29	12/03/2021		A		220,862		⁽¹¹⁾	01/26/2031	Common Stock	220,862	⁽¹²⁾	220,862	D

Explanation of Responses:

1. Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for 50,000 shares of common stock of Private Pear previously held by Mr. Maricich.

2. 100% of the shares subject to this option are fully vested and exercisable.

3. Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 50,000 shares of common stock of Private Pear for $0.02 per share.

4. Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 30,000 shares of common stock of Private Pear for $1.00 per share.

5. Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 120,000 shares of common stock of Private Pear for $0.20 per share.

6. Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 70,000 shares of common stock of Private Pear for $1.05 per share.

7. 25% of the shares underlying the option vested or shall vest on March 14, 2020 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.

8. Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 60,000 shares of common stock of Private Pear for $1.58 per share.

9. 25% of the shares underlying the option vested or shall vest on March 24, 2021 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.

10. Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 70,000 shares of common stock of Private Pear for $1.60 per share.

11. 25% of the shares underlying the option vested or shall vest on January 26, 2022 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.

12. Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 150,000 shares of common stock of Private Pear for $1.89 per share.

	/s/ Stacie S. Aarestad, Attorney-in-Fact	12/07/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC Form 4: Maricich Yuri was granted 73,620 shares